1. Home
  2. SPOT vs REGN Comparison

SPOT vs REGN Comparison

Compare SPOT & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SPOT
  • REGN
  • Stock Information
  • Founded
  • SPOT 2006
  • REGN 1988
  • Country
  • SPOT Luxembourg
  • REGN United States
  • Employees
  • SPOT N/A
  • REGN N/A
  • Industry
  • SPOT Broadcasting
  • REGN Biotechnology: Pharmaceutical Preparations
  • Sector
  • SPOT Consumer Discretionary
  • REGN Health Care
  • Exchange
  • SPOT Nasdaq
  • REGN Nasdaq
  • Market Cap
  • SPOT 131.0B
  • REGN 110.0B
  • IPO Year
  • SPOT 2018
  • REGN 1991
  • Fundamental
  • Price
  • SPOT $608.87
  • REGN $700.33
  • Analyst Decision
  • SPOT Buy
  • REGN Buy
  • Analyst Count
  • SPOT 29
  • REGN 26
  • Target Price
  • SPOT $544.61
  • REGN $996.00
  • AVG Volume (30 Days)
  • SPOT 2.3M
  • REGN 905.6K
  • Earning Date
  • SPOT 02-04-2025
  • REGN 02-04-2025
  • Dividend Yield
  • SPOT N/A
  • REGN 0.13%
  • EPS Growth
  • SPOT N/A
  • REGN 10.27
  • EPS
  • SPOT 5.69
  • REGN 38.34
  • Revenue
  • SPOT $16,226,317,429.00
  • REGN $14,202,000,000.00
  • Revenue This Year
  • SPOT $18.04
  • REGN $5.20
  • Revenue Next Year
  • SPOT $14.61
  • REGN $6.39
  • P/E Ratio
  • SPOT $111.83
  • REGN $18.27
  • Revenue Growth
  • SPOT 18.31
  • REGN 8.27
  • 52 Week Low
  • SPOT $247.95
  • REGN $642.00
  • 52 Week High
  • SPOT $652.63
  • REGN $1,211.20
  • Technical
  • Relative Strength Index (RSI)
  • SPOT 69.33
  • REGN 52.55
  • Support Level
  • SPOT $615.15
  • REGN $655.85
  • Resistance Level
  • SPOT $652.63
  • REGN $689.95
  • Average True Range (ATR)
  • SPOT 19.69
  • REGN 21.25
  • MACD
  • SPOT -1.19
  • REGN 2.98
  • Stochastic Oscillator
  • SPOT 82.80
  • REGN 63.22

About SPOT Spotify Technology S.A.

Spotify is the leading global music streaming service provider, with nearly 700 million monthly active users and over 250 million paying subscribers, with the latter comprising the firm's premium segment. most of the firm's revenue and nearly all its gross profit come from the subscribers, who pay a monthly fee to access a very comprehensive music library that consists of most of the most popular songs ever recorded, including all from the major record labels. The firm also sells separate audiobook subscriptions and integrates podcasts within its standard music app. Podcast content is not exclusive and is typically free to access on other platforms. Ad-supported users can access a similar music catalog but cannot customize a similar on-demand experience.

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).

Share on Social Networks: